CN Bio raises £17m in Series B funding from Bayland Capital and CN Innovations to scale operations
The financing round was backed by Bayland Capital and founding shareholder CN Innovations to accelerate product development and commercial expansion.
CN Bio is a leading provider of single-organ and multi-organ microphysiological systems designed to improve preclinical drug discovery. The company delivers advanced Organ-on-a-Chip solutions that reduce reliance on animal models and provide human-relevant data.
CN Bio has secured £17m in the first close of its Series B funding round to accelerate product development and scale its commercial operations. The investment was backed by new and existing stakeholders, including Bayland Capital and founding shareholder CN Innovations. The capital will support the company as it meets growing global demand for its Organ-on-a-Chip technology across key markets such as toxicology and metabolic diseases.
The financing follows a period of significant commercial momentum and regulatory milestones for the firm, including data support for clinical trial approvals in metabolic liver disease. By expanding its portfolio and R&D capabilities, CN Bio aims to enhance preclinical workflows for pharmaceutical developers and reduce late-stage clinical failures.
From the founder
"We are seeing pivotal growth across our industry, whereby drug developers are increasingly recognising the potential of OOC technology to augment, supplement and optimize their workflows."
Paul Brooks
CEO at CN Bio
Investor perspective
"OOC technology is an exciting market with compelling opportunity for growth. CN Bio has taken key steps to build a team with extensive industry expertise and robust networks across the industry, with a longstanding track record of success. We look forward to the continued success for the Company as it further capitalizes on this unique growth opportunity and delivers on its future expansion plans to remain at the cutting-edge of the field. We will leverage our networks and shareholders’ base to further support and cement the leading position of CN Bio in OOC development."
Yuexing Su
Founding Partner, Bayland Capital
Use of funds
- 01Continue product development
- 02Scale operations
Investors
Categories
About the company
CN Bio
CN Bio develops advanced Organ-on-a-Chip systems to transform human-relevant drug discovery.